LMGF(002734)2024-10-27 07:38Financial Performance - The company's operating revenue for Q3 2024 was ¥1,046,102,250.67, a decrease of 4.19% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥19,463,380.73, an increase of 154.77% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,416,384.03, up 112.93% from the previous year[2]. - Basic earnings per share for Q3 2024 was ¥0.05, reflecting a 150.00% increase compared to the same period last year[2]. - The company reported a decrease in accounts payable to CNY 660,298,556.45 from CNY 725,102,795.62 year-over-year[11]. - The net profit for the third quarter of 2024 was CNY 58,715,329, a significant increase from CNY 21,933,381 in the same period last year, representing a growth of approximately 167.0%[13]. - The operating profit for the third quarter was CNY 83,606,885.75, up from CNY 41,478,905.44 in the previous year, reflecting an increase of approximately 101.0%[13]. - The total comprehensive income for the third quarter was CNY 58,532,249.41, compared to CNY 22,722,457.77 in the previous year, representing an increase of approximately 157.0%[14]. Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥98,428,119.64, representing a significant decline of 283.08% year-on-year[2]. - The net cash flow from operating activities was -98,428,119.64 CNY, compared to 53,763,644.87 CNY in the previous year, indicating a significant decline[16]. - The company reported a total cash outflow from operating activities of 2,200,431,482.36 CNY, compared to 2,298,859,133.47 CNY in the previous year[16]. - Cash inflow from financing activities totaled 1,020,756,500.00 CNY, compared to 1,249,810,033.38 CNY in the previous year[16]. - The net cash flow from financing activities was -51,861,229.26 CNY, a decrease from a positive 160,137,280.48 CNY in the prior year[16]. - The ending balance of cash and cash equivalents was 354,847,793.11 CNY, down from 562,135,701.46 CNY year-over-year[16]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥6,774,182,758.51, a decrease of 0.60% from the end of the previous year[2]. - Current liabilities increased to CNY 2,888,965,758.76, compared to CNY 2,658,427,970.91 in the prior period[12]. - Non-current liabilities decreased to CNY 1,176,664,006.69 from CNY 1,341,753,924.71 year-over-year[12]. - The total equity attributable to shareholders of the parent company was CNY 2,660,189,944.01, down from CNY 2,773,342,822.67 in the previous year[12]. - Inventory decreased to CNY 671,099,704.87 from CNY 765,590,948.61 year-over-year[11]. - Long-term equity investments increased to CNY 314,193,363.06 from CNY 286,498,326.78 in the previous period[11]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,989[7]. - The largest shareholder, Li Ming, holds 20.10% of the shares, totaling 73,734,050 shares, with 48,120,851 shares pledged[7]. - The second-largest shareholder, Li Xinsong, holds 12.19% of the shares, totaling 44,737,620 shares, with 36,720,000 shares pledged[7]. Investment Activities - Investment income increased by 203.89% due to changes in the profitability of associated companies[5]. - The fair value change income surged by 1263.12%, primarily due to fluctuations in the fair value of trading financial assets[5]. - The company’s trading financial assets increased to ¥51,417,183.91 from ¥10,465,045.97, showing a substantial growth in investment activities[10]. - The company reported a net investment income of CNY 10,179,511.70, a turnaround from a loss of CNY 9,798,478.95 in the same period last year[13]. Research and Development - Research and development expenses for the quarter were CNY 102,781,588.30, slightly down from CNY 106,183,433.64 year-over-year, showing a decrease of about 3.8%[13]. Strategic Initiatives - The company signed a strategic cooperation agreement with Shanghai Zhisheng Yougu Biotechnology Co., Ltd. on September 23, 2024, to develop new RNA biopesticide products[9]. Accounting Changes - The company did not undergo an audit for the third quarter report[17]. - The company has adopted new accounting standards starting in 2024, affecting the financial statements[17].